Mecasermin (IGF-1 prescription product)
Increlex treats defined pediatric growth failure; do not confuse it with IGF-1 LR3.
Prescription-product label context
Increlex treats defined pediatric growth failure; do not confuse it with IGF-1 LR3.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Evidence and source limits
The July 2025 Increlex label identifies mecasermin for growth failure in patients age 2 years and older with severe primary IGF-1 deficiency, or with growth-hormone gene deletion and neutralizing antibodies to growth hormone.
This is not a general muscle-building, athletic recovery or healthy-aging indication. It must not be transferred to IGF-1 LR3 or a custom research preparation.
The label includes risks such as hypoglycemia, intracranial hypertension, hypersensitivity and malignant neoplasia. Read the full product label and discuss individual circumstances with a licensed clinician. No doses or treatment protocol are supplied.
Original source: Mecasermin (IGF-1 prescription product) ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.